Perspectives on diabetes

A1c and CVD – how low to go?

Perspectives on diabetes

A1c and CVD – how low to go?

Pat Phillips

Figures

Abstract

The target levels of glycosylated haemoglobin (A1c) for people with type 2 diabetes have been questioned following the findings of three recent trials of tight glycaemic control.

Article Extract

Tight treatment targets for people with diabetes have come into question with three recently published studies identifying no cardiovascular benefit of tight glycaemic control and one of these also demonstrating an increase in mortality rate. In all three studies, glycosylated haemoglobin (A1c) levels were significantly reduced in individuals with or at high risk of cardiovascular disease (CVD). These studies have an impact on the target levels of A1c recommended to people with type 2 diabetes.